This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Rinvoq
  • /
  • A Study Comparing Upadacitinib (ABT-494) Monothera...
Clinical trial

A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

Read time: 3 mins
Last updated:23rd Mar 2016
Identifier: NCT02706951

Brief Summary:
The study objective of Period 1 of this study is to compare the safety and efficacy (signs and symptoms) of upadacitinib 30 mg once daily (QD) alone and 15 mg QD alone versus continuing MTX alone adults with moderately to severely active rheumatoid arthritis (RA) with an inadequate response to MTX.

The study objective of Period 2 is to evaluate the long term safety, tolerability, and efficacy of upadacitinib 30 mg QD and 15 mg QD in adults with RA who had completed Period 1.

Detailed Description:
The study includes a 35-day screening period; a 14-week randomized, double-blind, parallel-group, controlled treatment period (Period 1); a 226-week blinded extension period (Period 2); and a 30-day follow-up visit.

Participants who met eligibility criteria were to be randomized in a 2:2:1:1 ratio to one of four treatment groups:
- Group 1: upadacitinib 30 mg QD (Period 1) → upadacitinib 30 mg QD (Period 2)
- Group 2: upadacitinib 15 mg QD (Period 1) → upadacitinib 15 mg QD (Period 2)
- Group 3: MTX (Period 1) → upadacitinib 30 mg QD (Period 2)
- Group 4: MTX (Period 1) → upadacitinib 15 mg QD (Period 2)


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 648 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to MTX
Actual Study Start Date: March 23, 2016
Actual Primary Completion Date: October 2, 2017
Estimated Study Completion Date: February 27, 2022

Arms:
- Experimental:
Upadacitinib 30 mg
- Experimental: Upadacitinib 15 mg
- Active Comparator: Methotrexate / Upadacitinib 30 mg
- Active Comparator: Methotrexate / Upadacitinib 15 mg

Category Value
Date last updated at source 2019-10-07
Study type(s) Interventional
Expected enrolment 648
Study start date 2016-03-23
Estimated primary completion date 2017-10-02

View full details